UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

• LEIDOS BIOMEDICAL RESEARCH INC

  UEI HV8BH9BPG8Y9

  $2.5M

  Subcontractor to this prime · 1 sub-award · latest Feb 4, 2026

  • National Institutes of Health
  • “COMPLETE THE HT-ATAC-SEQ HIGH THROUGHPUT SCREEN USING THIS ASSAY AND VALIDATE HIT MOLECULES.”
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  UEI C8H9CNG1VBD9

  $1.2M

  Subcontractor to this prime · 1 sub-award · latest Mar 22, 2024

  • National Institutes of Health
  • “OPTION 9B: 0258-A730-4609 RECOVERY AND IMMUNOLOGIC COMPARISONS ACROSS THE GROUP B MERBECOVIRUSES USING ANTIGENIC CARTOGRAPHY INTRODUCTION: MERBECOVIRUSES INCLUDE A DIVERSE ARRAY OF POSITIVE STRANDED RNA VIRUSES WITHIN THE BETACORONAVIRUS GENUS AND INCLUDE THE HIGHLY PATHOGENIC MERS-COV STRAIN THAT CAUSED 2604 LABORATORY-CONFIRMED CASES OF MIDDLE EAST RESPIRATORY SYNDROME (MERS) INCLUDING 936 ASSOCIATED DEATHS AT A CASE-FATALITY RATIO (CFR) OF 36% SINCE 2012. IMPORTANTLY, NUMEROUS ZOONOTIC BAT MERS-LIKE VIRUSES CIRCULATE IN NATURE INCLUDING SEVERAL STRAINS THAT CAN USE THE HUMAN DIPEPTIDYL PEPTIDASE RECEPTOR (HDPP4) FOR DOCKING AND ENTRY. SOME REPLICATE EFFICIENTLY OR ARE ANTICIPATED TO REPLICATE EFFICIENTLY IN PRIMARY HUMAN AIRWAY EPITHELIAL CELLS (E.G., MERS-422, MJHKU4R -COV-1, NEO, ), WHILE MOST HAVE NOT BEEN STUDIED. CURRENTLY, THERE ARE NO APPROVED VACCINES OR THERAPEUTICS FOR USE AGAINST MERS-COV INFECTION OR ANY OTHER MERBECOVIRUS. GIVEN THE EXTREME PATHOGENIC POTENTIAL OF MERS-COV, COUPLED WITH THE PRESENCE OF MERBECOVIRUSES THAT CAN USE DPP4 OR ANGIOTENSIN 1 CONVERTING ENZYME 2 (ACE2) AS RECEPTORS FOR DOCKING AND ENTRY, THE DEVELOPMENT OF PANMERBECOVIRUS VACCINES IS STILL CONSIDERED HIGH PRIORITY TARGETS FOR COUNTERMEASURE INVESTMENTS BY HEALTH AGENCIES ACROSS THE WORLD (HTTPS://WWW.WHO.INT/TEAMS/BLUEPRINT). THE OVERARCHING GOAL OF THIS PROPOSAL IS TO DETERMINE THE ANTIGENIC DISTANCE BETWEEN HIGHLY HETEROGENEOUS MERBECOVIRUSES, CREATE AN ANTIGENIC CARTOGRAPHY MAP, AND PRODUCE DEFINED SERA AND RECOMBINANT VIRUS REAGENTS THAT WILL ENHANCE GLOBAL PREPAREDNESS AGAINST FUTURE MERBECOVIRUS EPIDEMICS AND PANDEMICS. THE PROPOSAL HAS THREE AIMS: AIM I) PRODUCTION AND CHARACTERIZATION OF MERBECOVIRUS SPIKE ANTIGENS AND PRODUCTION OF MURINE ANTISERUM. FROM PUBLISHED SEQUENCES, MERBECOVRIRUS SPIKE GENES WILL BE SYNTHESIZED AND EXPRESSED AT UNC€„¢S PROTEOMIC CORE. RECOMBINANT PROTEINS PLUS ADJUVANT WILL BE INJECTED INTO RODENTS FOR THE PRODUCTION OF SERU”
• OREGON HEALTH & SCIENCE UNIVERSITY

  UEI NPSNT86JKN51 · not in the directory yet

  $811.4K

  Subcontractor to this prime · 1 sub-award · latest Nov 25, 2024

  • National Institutes of Health
  • “DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE”
• DUKE UNIVERSITY

  UEI TP7EK8DZV6N5

  $600.8K

  Subcontractor to this prime · 1 sub-award · latest Feb 14, 2025

  • National Institutes of Health
  • “THE OVERALL GOAL OF THIS PROJECT IS TO EVALUATE VARIOUS ADJUVANTS AND COMBINATIONS OF THESE ADJUVANTS FOR USE IN MUCOSAL IMMUNOTHERAPY FOR PEANUT ALLERGY. DR. KULIS AND HIS TEAM AT UNC CHAPEL HILL WILL PERFORM IN VIVO MOUSE STUDIES, ASSAY HUMAN PERIPHERAL BLOOD CELLS, AND QUANTIFY IMMUNOLOGIC RESPONSES TO ADJUVANTS AND PEANUT FROM BOTH MOUSE AND HUMAN BLOOD. SPECIFICALLY, WE WILL EVALUATE SIX ADJUVANT FORMULATIONS IN CELL CULTURE ASSAYS WITH HUMAN T AND B CELLS FROM BLOOD, PRIMARILY INVESTIGATING CYTOKINE RESPONSES AND THEN SENDING CELLS FROM THESE EXPERIMENTS TO DUKE FOR OMICS EXPERIMENTS. FOR THE MOUSE STUDIES, WE WILL EVALUATE THE SAME SIX ADJUVANTS PLUS PEANUT BY ADDING THE ADJUVANTS TO SPLEEN AND LYMPH NODE CELLS IN CULTURE. WE WILL ALSO ADMINISTER THE ADJUVANTS AND PEANUT BY THE SUBLINGUAL ROUTE TO LIVE MICE THAT ARE EITHER NOT SENSITIZED TO PEANUT OR IN MICE THAT HAVE AN ESTABLISHED PEANUT ALLERGY. WE WILL PERFORM THESE EXPERIMENTS AT UNC, AND ALSO SAVE VARIOUS SAMPLES (SPLEEN, LYMPH NODE, SERUM, SALIVA, AND FECAL PELLETS) TO SHIP TO DUKE FOR OMICS STUDIES. ULTIMATELY, THE SIX ADJUVANTS WILL BE EVALUATED FOR THEIR SAFETY AND EFFICACY IN THE PEANUT ALLERGIC MICE. SINCE THIS PROJECT INVOLVES TEAM MEMBERS AT DUKE AND INIMMUNE, WE WILL ALSO PARTICIPATE IN BIWEEKLY MEETINGS TO DISCUSS EXPERIMENTAL DESIGN, PROGRESS, AND DATA ANALYSIS. TWO TEAM MEMBERS FROM UNC (DR. KULIS AND DR. SMEEKENS) WILL ATTEND ANNUAL MEETINGS AT NIH IN BETHESDA, MD. WE ANTICIPATE PUBLISHING SEVERAL MANUSCRIPTS BASED ON THE WORK DONE AT UNC IN COLLABORATION WITH DUKE AND INIMMUNE, WHICH THE UNC TEAM WILL BE HEAVILY INVOLVED IN WRITING.”
• UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  UEI NMJHD63STRC5

  $503K

  Subcontractor to this prime · 1 sub-award · latest Oct 28, 2025

  • National Institutes of Health
  • “CENTER FOR INFLUENZA VACCINE RESEARCH FOR HIGH RISK POPULATIONS”
• UNIVERSITY OF DELAWARE

  UEI T72NHKM259N3

  $450K

  Subcontractor to this prime · 1 sub-award · latest May 19, 2025

  • Department of the Army
  • “WE AIM AT DEMONSTRATING A MODULE EFFICIENCY OF FLEXIBLE MINIMODULES TO BE COMPARABLE TO THAT OF RIGID MINIMODULES WITH AREA >25 CM2 AND PASSING 1 SUN ILLUMINATION (LED) STABILITY TEST AT MAXIMUM POWER POINT FOR 1000 HOURS AND BENDING OF 5000 TIMES WITH EFFICIENCY LOSS OF LESS THAN 10%.”
• HONEYWELL FEDERAL MANUFACTURING & TECHNOLOGIES, LLC

  UEI DMEGBYTVBQS5

  $400K

  Subcontractor to this prime · 4 sub-awards · latest Jan 26, 2026

  • Department of Energy
  • “R&D”
  • “RESEARCH AND DEVELOPMENT”
• RESEARCH TRIANGLE INSTITUTE

  UEI JJHCMK4NT5N3

  $379K

  Subcontractor to this prime · 1 sub-award · latest May 21, 2026

  • Office of the Assistant Secretary for Financial Resources
  • “PO RTI1004077 SUBCONTRACT 370 INITIAL AWARD”
• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $150K

  Subcontractor to this prime · 1 sub-award · latest Jan 29, 2025

  • Department of Energy
  • “UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL-STANDALONE-ITEM LEVEL-R AND D”
• LEIDOS, INC.

  UEI QLNMVC12KWY3

  $140.4K

  Subcontractor to this prime · 1 sub-award · latest Nov 10, 2025

  • Department of the Navy
  • “PROCURED GOODS AND/OR SERVICES BETWEEN 10-NOV-25 AND 01-SEP-26 IN SUPPORT OF CONTRACT SOW.”
• FRED HUTCHINSON CANCER CENTER

  UEI TJFZLPP6NYL6

  $99.8K

  Subcontractor to this prime · 1 sub-award · latest Apr 24, 2026

  • National Institutes of Health
  • “PER WHI POLICY, EVENTS ELIGIBLE FOR INVESTIGATION FOR HEART FAILURE WILL BE IDENTIFIED BY WHI STAFF. MEDICAL RECORDS WILL BE OBTAINED FOR ELIGIBLE HOSPITALIZATION AND SENT TO WHI REGIONAL CENTERS FOR INITIAL VERIFICATION AND DETERMINATION OF COMPLETENESS. ELECTRONIC COPIES OF ASSEMBLED MEDICAL RECORDS ARE SENT TO THE COORDINATING CENTER AT THE UNIVERSITY OF NORTH CAROLINA. THE UNC COORDINATING CENTER RECEIVES LOGS AND VERIFIES RECEIPT OF MEDICAL RECORDS. UNC COORDINATING CENTER WILL USE A WEB-BASED DATA ENTRY SYSTEM FOR THE WHI HEART FAILURE DATA ABSTRACTION AND FOR CAPTURING THE PHYSICIAN ADJUDICATOR CLASSIFICATION. TRAINED MEDICAL RECORDS ABSTRACTORS WILL REVIEW RECORDS AND COMPLETE HEART FAILURE DATA COLLECTION TOOL. NUMBER OF HEART FAILURE ELIGIBLE CASES ESTIMATED TO BE IDENTIFIED BY WHI AND SENT TO THE UNC COORDINATING CENTER FOR ABSTRACTION AND CLASSIFICATION: YEAR 6 = 250 YEAR 7 = 250”
• UNIVERSITY OF CONNECTICUT

  UEI WNTPS995QBM7

  $40K

  Subcontractor to this prime · 1 sub-award · latest Jun 30, 2026

  • Department of the Army
  • “PREDICTING CARBON SINK STRENGTH IN DOD COASTAL WETLANDS - A SIMPLE TRANSFERABLE EMPIRICAL APPROACH”

• GEORGETOWN UNIVERSITY

  UEI TF2CMKY1HMX9

  $1.1M

  Subcontracted by this company · 1 sub-award · latest May 7, 2024

  • National Institutes of Health
  • “THE SCOPE OF WORK AT THE GEORGETOWN UNIVERSITY LABORATORY WILL INCLUDE THE CONTINUED USE OF ITS LIBRARY OF CELL LINES THAT STABLY EXPRESS DIFFERENT SUBTYPES OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS (NACHRS) TO SCREEN COMPOUNDS SENT TO THE PDSP FROM LABORATORIES THROUGHOUT THE U.S. FOR ACTIVITY AT NACHR SUBTYPES. THE COMPOUNDS THAT DISPLAY HIGH AFFINITY FOR ANY OF THE NACHRS ARE FURTHER EXAMINED IN FUNCTIONAL ASSAYS. THOSE COMPOUNDS WHICH HAVE VERY FAST CHANNEL KINETICS THAT MAKE IT VIRTUALLY IMPOSSIBLE TO ACCURATELY MEASURE ITS FUNCTION WITH BIOCHEMICAL METHODS, THE LAB WILL CONTINUE TO MEASURE ITS ION CHANNEL FUNCTION ELECTRO-PHYSIOLOGICALLY VIA FAST PATCH CLAMP METHODS.”
• REGENTS OF THE UNIVERSITY OF MINNESOTA

  UEI KABJZBBJ4B54

  $682.1K

  Subcontracted by this company · 1 sub-award · latest Mar 14, 2025

  • National Institutes of Health
  • “THE UNIVERSITY OF MINNESOTA (UM) RESEARCHERS WILL BE THE CENTRAL LABORATORY FOR THE STUDY TITLED "HISPANIC COMMUNITY HEALTH STUDY-STUDY OF LATINOS (HCHS-SOL) COORDINATION CENTER". UM WILL COMPLETE THE FOLLOWING TASKS: A5. ESTABLISH AND MANAGE THE BIOLOGICAL SPECIMEN REPOSITORY; A5A. MAINTAIN THE HCHS/SOL BIOLOGIC SPECIMEN REPOSITORY IN ACCORDANCE WITH HCHS/SOL POLICIES AND PROCEDURES; A5B. INCORPORATE SURPLUS SPECIMENS FROM ANCILLARY STUDIES; A5C. TRACK SAMPLES; A5D. PROVIDE SPECIMENS TO APPROVED INVESTIGATORS IN ACCORDANCE WITH STUDY POLICIES AND PROCEDURES; A5E. CONDUCT QUALITY MANAGEMENT PROCEDURES; B2.3. PLAN AND CONDUCT THE RECEIPT AND PROCESSING OF COLLECTED BLOOD AND URINE SAMPLES; B2.5. TRAINING OF RELEVANT STAFF AT ALL FIELD CENTERS; C.3. PROVIDE SMOOTH TRANSFER OF ALL BIOLOGICAL SAMPLES; C.4. PREPARE AN APPLICATION FOR TRANSFER OF BIOLOGICAL SPECIMENS TO THE NHLBI BIOSPECIMEN REPOSITORY; C.5. SHIP ALL BIOLOGICAL SAMPLES TO THE NHLBI BIOSPECIMEN REPOSITORY AND/OR OTHER BIOREPOSITORIES.”

No active exclusion on record (checked Nov 14, 2026).

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 14, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.